Cross-Sector entity
Of the tracked stories, 4 of 4 also mention Weiss Ratings, the most common co-covered peer. Coverage clusters in e-commerce, which accounts for 1 of those 4, with the remainder spread across 3 other categories. The tracked stories average 2 original sources each.
4 verified stories tracked
Last mentioned: Aug 16, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 4 of 4 also mention Weiss Ratings, the most common co-covered peer. Coverage clusters in e-commerce, which accounts for 1 of those 4, with the remainder spread across 3 other categories. The tracked stories average 2 original sources each. Two Sigma Investments LP appears in 4 tracked Cross-Sector stories published from August 12, 2026 through August 16, 2026.
Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Two Sigma Investments LP. Shared-story counts are live from our verified record — not editorial picks.
Quarterly earnings release
Lantern Pharma reported quarterly EPS of ($0.57), missing consensus by $0.19; shares rose $0.02 to $2.65.
Weiss Ratings upgrade
Weiss Ratings upgraded Lantern Pharma from 'sell (e+)' to 'sell (d-)'.
Wall Street Zen rating action
Research note on LTRN reported with conflicting direction across sources (upgrade to hold vs downgrade to sell).
Lantern Pharma's quarterly EPS miss of $0.19 highlights the cash-intensive nature of AI-powered oncology drug discovery. The clinical-stage company has no product revenue, and its stock trades well below moving averages. Healthcare executives should monitor its platform and funding runway rather than quarterly losses.
Lantern Pharma missed quarterly EPS estimates by $0.19, but shares rose 0.76% to $2.65 on double average volume. The micro-cap trades below both moving averages with a beta of 2.34 and a Sell consensus. Institutional accumulation is scattered and small.
Lantern Pharma's $0.57 quarterly loss missed consensus by $0.19, underscoring clinical-stage risk. The micro-cap oncology company has no product revenue, and analysts maintain a Sell rating. Biotech investors need clarity on cash runway and upcoming trial catalysts.
Source: dailypolitical.com · themarketsdaily.com
Cardlytics, whose platform powers cashback offers inside banking apps for major retailers, is under financial strain—its stock has plummeted to $4.37 and the CEO has unloaded shares. The company’s tiny $25M market cap and negative earnings put its future in doubt, directly affecting retail brands that depend on it for consumer acquisition and loyalty campaigns.
Source: dailypolitical.com · themarketsdaily.com
